Aptinyx Inc. (NASDAQ:APTX) Receives Average Recommendation of “Buy” from Brokerages

Shares of Aptinyx Inc. (NASDAQ:APTXGet Rating) have been given an average rating of “Buy” by the seven analysts that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $4.40.

APTX has been the subject of several research reports. SVB Leerink cut their price target on Aptinyx from $10.00 to $4.00 and set an “outperform” rating for the company in a report on Thursday, April 21st. Zacks Investment Research downgraded Aptinyx from a “buy” rating to a “hold” rating in a report on Friday, April 22nd. Truist Financial cut their price target on Aptinyx from $12.00 to $5.00 and set a “buy” rating for the company in a report on Friday, April 8th. William Blair downgraded Aptinyx from an “outperform” rating to a “market perform” rating in a report on Thursday, April 7th. Finally, HC Wainwright cut their price target on Aptinyx from $8.00 to $2.00 and set a “buy” rating for the company in a report on Thursday, April 14th.

NASDAQ:APTX opened at $0.88 on Tuesday. Aptinyx has a 1-year low of $0.87 and a 1-year high of $4.73. The company has a current ratio of 20.18, a quick ratio of 20.18 and a debt-to-equity ratio of 0.15. The firm has a fifty day simple moving average of $2.21 and a 200 day simple moving average of $2.52. The stock has a market capitalization of $59.59 million, a PE ratio of -0.79 and a beta of 1.46.

Aptinyx (NASDAQ:APTXGet Rating) last released its earnings results on Wednesday, March 23rd. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.06. During the same quarter in the prior year, the firm earned ($0.20) earnings per share. On average, equities analysts predict that Aptinyx will post -1.1 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Assenagon Asset Management S.A. acquired a new stake in shares of Aptinyx during the first quarter worth $155,000. BlackRock Inc. raised its stake in Aptinyx by 1.5% in the fourth quarter. BlackRock Inc. now owns 1,374,768 shares of the company’s stock valued at $3,669,000 after purchasing an additional 20,928 shares in the last quarter. Susquehanna International Group LLP raised its stake in Aptinyx by 56.8% in the fourth quarter. Susquehanna International Group LLP now owns 243,275 shares of the company’s stock valued at $650,000 after purchasing an additional 88,141 shares in the last quarter. Millennium Management LLC raised its stake in Aptinyx by 19.7% in the fourth quarter. Millennium Management LLC now owns 1,246,945 shares of the company’s stock valued at $3,329,000 after purchasing an additional 205,553 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Aptinyx in the fourth quarter valued at about $448,000. 55.97% of the stock is owned by institutional investors.

Aptinyx Company Profile (Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

Read More

Analyst Recommendations for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.